文献速递肝病

代谢功能障碍相关脂肪性肝炎临床试验中的安慰剂效应:系统综述与荟萃分析

Placebo Rates in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-11-04

该系统综述与荟萃分析纳入127项安慰剂对照试验共6880例MASH患者,量化安慰剂反应率。非肝硬化患者安慰剂组MASH缓解且纤维化不恶化的合并比例为11%(95%CI 8%-14%),肝硬化患者MELD评分从<12升至≥15的比例为4%(95%CI 1%-13%)。安慰剂反应率因结局指标而异,总体偏高。

要点

  • 非肝硬化MASH安慰剂组MASH缓解且纤维化不恶化比例为11%(95%CI 8%-14%)。
  • 肝硬化MASH安慰剂组MELD评分从<12升至≥15比例为4%(95%CI 1%-13%)。
  • 安慰剂组ALT正常化比例12%,肝脂肪含量绝对下降5%比例22%。

核心结论

  • MASH患者中安慰剂反应率总体偏高,且因所测结局指标不同而差异较大。
  • 本研究为优化未来MASH试验设计提供了参考信息。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL自建库至2025年5月7日的MASH药物干预安慰剂对照试验。
  • 共纳入127项研究、6880例参与者。
  • 采用随机效应模型合并安慰剂反应率,并用荟萃回归评估患者和试验设计因素对主要结局的影响。

主要发现

  • 非肝硬化安慰剂患者达到MASH缓解且纤维化不恶化的合并比例为11%(95%CI 8%-14%)。
  • 荟萃回归未发现与安慰剂反应相关的显著患者或试验特征。
  • 肝硬化安慰剂患者MELD评分从<12升至≥15的比例为4%(95%CI 1%-13%)。
  • 安慰剂患者ALT正常化比例为12%(95%CI 8%-18%)。
  • 安慰剂患者肝脂肪含量绝对下降5%的比例为22%(95%CI 18%-27%),相对下降30%的比例为19%(95%CI 16%-22%),进展为肝硬化的比例为2%(95%CI 0.7%-3%)。

临床怎么用

  • 解读MASH临床试验结果时应考虑不同结局指标对应的安慰剂反应率差异。
  • 试验设计可参考本研究报告的安慰剂反应率区间进行样本量估算和终点选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: High placebo response rates complicate drug development in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials. We performed a meta-analysis to quantify placebo response and assess influencing factors. METHODS: MEDLINE, Embase, and CENTRAL were searched from inception to May 7, 2025, for placebo-controlled trials of pharmacological interventions for MASH. Placebo response rates were pooled by random-effects model and meta-regression was used to evaluate the effects of patient and trial design factors on the primary outcomes. RESULTS: A total of 127 studies (6880 participants) were included. For the primary outcome, the pooled proportion of noncirrhotic placebo patients achieving MASH resolution without worsening of fibrosis was 11% (95% confidence interval [CI], 8%-14%). Meta-regression did not identify any significant patient or trial characteristics associated with placebo response. For the second primary outcome, the proportion of cirrhotic placebo patients whose Model for End-Stage Liver Disease score increased from below 12 to ≥15 was 4% (95% CI, 1%-13%). Regarding secondary outcomes, 12% (95% CI, 8%-18%) of placebo patients achieved normal alanine aminotransferase levels, and 22% (95% CI, 18%-27%) showed an absolute reduction of 5% in hepatic fat content. Additionally, 19% of placebo patients (95% CI, 16%-22%) achieved a relative reduction of 30% in fat content, while 2% (95% CI, 0.7%-3%) progressed to cirrhosis. CONCLUSIONS: Placebo response rates among patients with MASH are generally elevated yet vary considerably depending on the outcome measured. This study provides valuable insights to enhance the design of future MASH trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Idalsoaga F, Díaz LA, Alghsoon S, et al. Placebo Rates in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2025. PMID: 41076041. doi:10.1016/j.cgh.2025.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。